NeoGenomics (NEO) Investor presentation summary

Strategic positioning and market opportunity

• Focuses exclusively on oncology solutions, leveraging a strong commercial organization to drive innovation adoption.

• Holds a leadership position in hematology, expanding into solid tumor therapy selection and MRD markets.

• Entering the $20B+ solid tumor MRD market with the RaDaR ST product launch.

• Breadth of test menu and community oncology focus differentiates from large reference labs.

• Achieved double-digit revenue growth and ten consecutive quarters of positive adjusted EBITDA.

Product portfolio and innovation

• Offers comprehensive cancer testing from diagnosis to recurrence monitoring, including flagship products like PanTracer and RaDaR ST.

• RaDaR ST enables ultra-sensitive MRD detection, with reimbursement secured for head & neck and breast cancer indications.

• PanTracer Pro streamlines ordering and accelerates therapy decisions, including over 12 companion diagnostic IHC tests.

• Product upgrades and expanded indications are key levers for growth.

Community oncology focus

• 80% of cancer patients receive care in the community setting, with most living over an hour from major cancer centers.

• Precision oncology solutions are tailored for community practices, offering ease of ordering, fast turnaround, and comprehensive menus.

• Net Promoter Score of 78 reflects strong physician satisfaction.